Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca's lengthy and turbulent development ... The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's ...

I pine for the good old days of man flu, where the slightest symptom, a cough, a sniffle or a general sense of malaise, could ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

AstraZeneca has added to its oncology pipeline ... and Mirati’s Krazati (adagrasib), which have been approved as second-line therapies for KRAS-mutated non-small cell lung cancer (NSCLC ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The second scenario consisted of cases in which people received a booster dose of CoronaVac as well ... there are also the viral vector vaccines (AstraZeneca and Janssen), in which another ...

Beth was volunteering on a phase one medical trial. It’s the first stage in testing new drugs on humans, in which healthy ...

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.